About 0.3% of the world’s population has schizophrenia, which translates to roughly 24 million people. That figure comes from the World Health Organization, which puts the rate at 1 in 345 people across all ages. Among adults specifically, the rate is higher: about 0.43%, or 1 in 233 people.
Why Two Different Numbers Exist
You’ll often see schizophrenia prevalence quoted as anywhere from 0.3% to nearly 1%, depending on the source. The difference comes down to how prevalence is measured. The WHO’s 0.29% figure counts everyone alive right now who has the condition, including children and adolescents who almost never develop it. When you narrow the count to adults only, the rate jumps to 0.43% because you’ve removed a large chunk of the population that’s essentially at zero risk.
Lifetime prevalence, which estimates how many people will develop schizophrenia at some point during their life, tends to run higher still, often cited between 0.5% and 1%. That number includes people who had episodes in the past but may no longer meet diagnostic criteria. The figure you see depends entirely on which question is being asked: who has it right now, or who will ever have it.
Who Gets Schizophrenia and When
Men and women develop schizophrenia at roughly equal rates over a lifetime, but the pattern looks different for each. Men are diagnosed about 1.4 times more often than women in any given year, largely because they develop the condition earlier. The average age of onset for men is around 24, compared to about 28 for women. Men typically show their first symptoms in late adolescence or their early twenties, while women peak in their mid-to-late twenties and sometimes experience a second, smaller wave of onset around midlife.
This earlier onset in men has real consequences. Developing schizophrenia during the teens or early twenties can interrupt education, career development, and the social skills people build during that period. The later onset in women is one reason their overall course tends to be somewhat less severe on average, though the condition is serious regardless of when it appears.
Does Prevalence Vary by Country?
Schizophrenia shows up in every country and culture researchers have studied, but pinning down whether some regions have genuinely higher rates is surprisingly difficult. Annual incidence rates across studies range from 0.04 to 0.58 per 1,000 people, a wide spread. Much of that variation, though, likely reflects differences in how studies are designed rather than true geographic differences. Diagnostic criteria, access to mental health professionals, and cultural factors in reporting symptoms all muddy the comparison.
One consistent and unexpected finding is that the long-term course of schizophrenia appears to be more favorable in lower-income countries, even where treatment options are limited. Researchers have debated the reasons for decades, with theories ranging from stronger family support networks to less social isolation, but no single explanation has been confirmed.
What Causes It
Schizophrenia is one of the most heritable psychiatric conditions. Twin studies estimate that genetics account for about 81% of the risk, with shared environmental factors contributing roughly 11%. But high heritability doesn’t mean a single gene is responsible. Hundreds of small genetic variations each contribute a tiny amount of risk, and having a family member with schizophrenia raises your chances without making the condition inevitable.
Environment still matters, especially for people who carry genetic vulnerability. Adoption studies from Finland found that children born to mothers with schizophrenia were significantly more likely to develop the condition themselves if they were raised in highly dysfunctional households, but not if their adoptive families were stable. Danish research found similar results: genetic risk combined with unstable parenting or institutional care increased the likelihood of schizophrenia far more than either factor alone. This gene-environment interaction means that genetic predisposition loads the gun, but life circumstances play a role in whether it fires.
How It’s Diagnosed
A diagnosis requires more than a brief psychotic episode. Under the most widely used international criteria, psychotic symptoms like hallucinations, delusions, or disorganized thinking must persist for at least one month. The American diagnostic system sets a higher bar, requiring some form of symptoms to last at least six months, with at least one month of active psychotic features. In both systems, doctors must rule out substance use, other medical conditions, and mood disorders that can mimic schizophrenia before making the diagnosis.
Modern diagnostic frameworks also recognize that schizophrenia involves more than hallucinations and delusions. Clinicians now assess a range of symptom dimensions, including cognitive difficulties like trouble with memory and attention, loss of motivation or emotional expression, and mood symptoms like depression. These “negative” and cognitive symptoms are often more disabling in daily life than the more dramatic psychotic episodes.
The Impact on Health and Life Expectancy
Schizophrenia ranks among the most disabling conditions worldwide. Globally, the age-standardized disability rate sits at roughly 221 per 100,000 people, and projections suggest this burden will increase in coming decades. The disability comes not just from active symptoms but from the cognitive and motivational difficulties that make holding a job, maintaining relationships, and living independently a daily challenge.
People with schizophrenia also die significantly earlier than the general population, with life expectancy reduced by 10 to 15 years. For men, the gap can reach nearly 15 years. Some of this is due to suicide, which affects roughly 5% of people with the condition over their lifetime. But the larger driver is physical health: people with schizophrenia have much higher rates of heart disease, diabetes, and metabolic problems, partly from medications, partly from lifestyle factors tied to the illness, and partly because their physical health complaints are often overlooked or undertreated by medical systems.
The Global Treatment Gap
Despite being a well-recognized condition with effective treatments, a large proportion of people with schizophrenia worldwide receive no formal care. The WHO has repeatedly highlighted this treatment gap, which is widest in low- and middle-income countries where mental health infrastructure is minimal. In some regions, the majority of people experiencing psychosis never see a mental health professional.
Even in wealthier countries, delays between the first psychotic episode and treatment are common, often stretching months or years. This matters because longer untreated psychosis is consistently linked to worse long-term outcomes. Early intervention programs that combine medication with psychological support and social services have shown strong results, but they remain unavailable to most of the world’s population living with the condition.